Top

Journal of Hepato-Biliary-Pancreatic Sciences

Published in:

01-11-2012 | Original article

Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine

Authors: Natsuko Kawada, Hiroyuki Uehara, Kazuhiro Katayama, Satoaki Nakamura, Hidenori Takahashi, Hiroaki Ohigashi, Osamu Ishikawa, Shigenori Nagata, Yasuhiko Tomita

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 6/2012

Abstract

Background

Gemcitabine is a key drug for the treatment of pancreatic cancer. Human equilibrative nucleoside transporter 1 (hENT1) is a major transporter responsible for gemcitabine uptake into cells. This study was conducted to elucidate the association between expression level of hENT1 and outcome for pancreatic cancer patients treated with neoadjuvant therapy including gemcitabine.

Methods

Sixty-three patients who underwent neoadjuvant chemoradiation followed by curative surgery for pancreatic ductal adenocarcinomas were included. Immunohistochemistry was performed using resected specimens and the staining intensity of hENT1 was scored as having no staining, low staining, or high staining; the former two were defined as negative expression of hENT1. The association between expression level of hENT1 and overall survival was evaluated by Cox proportional regression model.

Results

Expression level of hENT1 was evaluated as positive in 22 (35%) patients, and as negative in 41 (65%) patients. Univariate analysis showed that regional lymph node metastasis, vascular permeation, and perineural invasion are prognostic factors; however, expression level of hENT1 did not reach statistical significance. Multivariate analysis showed only vascular permeation as a prognostic factor.

Conclusions

Expression level of hENT1 was not associated with prognosis for pancreatic cancer patients who were treated with neoadjuvant chemoradiation including gemcitabine.

Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and in clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. A randomized trial. J Clin Oncol. 1997;15:2403–13.PubMed

Abbruzzese JL. New applications of gemcitabine and future direction in the management of pancreatic cancer. Cancer. 2002;95:941–5.PubMedCrossRef

Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998;58:4349–57.PubMed

Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst (Bethesda). 1999;91:1876–81.CrossRef

Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res. 2011;71(5):1825–35.PubMedCrossRef

Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, et al. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets. 2011;11:123–9.PubMedCrossRef

Matsumura N, Nakamura Y, Kohjimoto Y, Inagaki T, Nanpo Y, Yasuoka H, et al. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int. 2010;108:E110–6.PubMedCrossRef

Oguri T, Achiwa H, Muramatsu H, Ozasa H, Sato S, Shimizu S, et al. The absence of human equilibrative transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 2007;256:112–9.PubMedCrossRef

Mackey JR, Jennings LL, Clarke ML, Santos CL, Dabbagh L, Vsianska M, et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res. 2002;8:110–6.PubMed

10.

Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136:187–95.PubMedCrossRef

11.

Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009;15(8):2913–9.PubMedCrossRef

12.

Spratlin J, Sangha R, Glubrect D, Young JD, Dumontet C, Cass C, Lai R, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 2004;10:6956–61.PubMedCrossRef

13.

Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250:88–95.PubMedCrossRef

14.

Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.PubMedCrossRef

15.

Golcher H, Brunner T, Grabenbauer G, Merkel S, Papadopoulos T, Hohenberger W, et al. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol. 2008;34:756–64.PubMedCrossRef

16.

Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, et al. A multi-institutional phase II trail of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150–8.PubMedCrossRef

17.

Ishikawa O, Ohigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, et al. Practical usefulness of lymphatic and connective tissue clearance for carcinoma of the pancreas head. Ann Surg. 1988;208:215–20.PubMedCrossRef

18.

Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.PubMedCrossRef

19.

Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene. 2003;22:7524–36.PubMedCrossRef

20.

Dingle BH, Rumble RB, Brouwers MC. Cancer Care Ontario’s program in evidence-based care’s gastrointestinal cancer diseases site group. The role of gemcitabine in the treatment of cholangiocarcinoma and gall-bladder cancer: a systemic review. Can J Gastroenterol. 2005;19:711–6.PubMed

21.

Pasetto LM, D’Andrea MR, Falci C, Monfardini S. Gemcitabine in advanced biliary tract cancers. Crit Rev Oncol Hematol. 2007;61:230–42.PubMedCrossRef

22.

Santini D, Perrone G, Vincenzi B, Lai C, Cass R, Alloni C, et al. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer. Ann Oncol. 2008;19:724–8.PubMedCrossRef

23.

Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, et al. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol. 2010;223:384–8.PubMed

Title: Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine
Authors: Natsuko Kawada
Hiroyuki Uehara
Kazuhiro Katayama
Satoaki Nakamura
Hidenori Takahashi
Hiroaki Ohigashi
Osamu Ishikawa
Shigenori Nagata
Yasuhiko Tomita
Publication date: 01-11-2012
Publisher: Springer Japan
Published in: Journal of Hepato-Biliary-Pancreatic Sciences / Issue 6/2012
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI: https://doi.org/10.1007/s00534-012-0514-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2012

Living-donor liver transplantation for moderate or severe porto-pulmonary hypertension accompanied by pulmonary arterial hypertension: a single-centre experience over 2 decades in Japan

Recent advances in cancer stem cell research for cholangiocarcinoma

Clinical impact of right accessory hepatic artery injury in deceased donor livers

Area between the hepatic and heart curves of 99mTc-galactosyl-human serum albumin scintigraphy represents liver function and disease progression for preoperative evaluation in hepatocellular carcinoma patients

Basics and applications of stem cells in the pancreas

Proposed indications for limited resection of early ampulla of Vater carcinoma: clinico-histopathological criteria to confirm cure